71% of women regained weight within 12 weeks of stopping semaglutide, driven by reversal of gut microbiota changes and reactivation of brain hunger signals — though some metabolic improvements persisted.
71.4% regained weightWithin just 12 weeks of stopping semaglutide, nearly three-quarters of women who lost an average of 16.9 kg began regaining weight, with gut microbiota reversal as a key mechanism
What the researchers found
After 36 weeks of semaglutide treatment, 28 women with obesity lost an average of 16.9 kg. But within 12 weeks of stopping the drug, 71.4% regained weight (averaging +5.1 kg) and 78.5% experienced appetite rebound (≥30% increase in hunger scores plus ≥300 kcal/day increase in intake).
The mechanistic investigation — using both human data and parallel rat studies — found that weight regain was accompanied by gut microbiota dysbiosis (increased Firmicutes/Bacteroidota ratio), decreased ursodeoxycholic acid levels, reduced hypothalamic TGR5 expression, and reactivation of hunger-promoting brain signals (AgRP/NPY) while satiety signals (POMC/MC4R) weakened. However, some improvements in liver and fat tissue metabolism partially persisted through maintained AMPK/SIRT1 activation.
Why it matters
The biggest criticism of GLP-1 drugs is that weight returns when you stop taking them. This study is one of the first to systematically explain WHY that happens — tracing the mechanism from gut bacteria changes to bile acid shifts to brain appetite center reactivation. Understanding this pathway could lead to strategies that prevent post-drug weight regain.
The numbers in context
n=28 women · 36 weeks treatment · 12 weeks withdrawal · Weight loss: -16.9 ± 4.8 kg · Weight regain: +5.1 ± 1.6 kg in 71.4% · Appetite rebound: 78.5% · ≥300 kcal/day increase
How the study worked
Prospective, single-arm interventional study in 28 women with obesity receiving semaglutide 2.4 mg/week for 36 weeks followed by 12-week withdrawal monitoring. Parallel animal studies used high-fat diet female rats with 4-week semaglutide intervention and 4-week withdrawal. Measured body weight, metabolic parameters, gut microbiota composition (16S sequencing), bile acid profiles, and hypothalamic gene expression.
Who was studied
28 women with obesity (human study) plus high-fat diet female rats (parallel animal study)
What this study cannot tell us
Small sample size (28 women) with no control group in the human portion. Single-arm design means natural weight fluctuations can't be separated from drug withdrawal effects. Only studied women. The 12-week withdrawal period may not capture the full trajectory of weight regain. Animal model findings may not fully translate to humans. Gut microbiota changes are correlative, not definitively causal.
How to read the evidence
Rated moderate because it combines a prospective human study with mechanistic animal work, providing both clinical observations and biological explanations. However, the human portion is small (n=28), single-arm, and without a control group, limiting causal conclusions.
When this study was published
Published in 2026, this is cutting-edge research addressing one of the most pressing questions in obesity medicine — the sustainability of GLP-1-mediated weight loss.
The bigger picture
The 'what happens when you stop' question is the central challenge for GLP-1 drug therapy. This study provides a biological roadmap for why weight regain occurs — implicating the gut-brain axis through microbiota and bile acid changes. If these pathways can be targeted (e.g., with probiotics, bile acid supplements, or maintaining therapy), it could solve the sustainability problem that currently requires most patients to stay on GLP-1 drugs indefinitely.
Questions still open
- Could probiotics or prebiotics maintain the beneficial gut microbiota changes and prevent post-semaglutide weight regain?
- Would a gradual dose taper instead of abrupt withdrawal reduce the rebound effect?
- Do the partially maintained metabolic improvements (AMPK/SIRT1 activation) protect against the full metabolic consequences of weight regain?
Common questions
Do you gain weight back after stopping semaglutide?
Why does weight come back after stopping semaglutide?
Read the original research
Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.
Diabetes, obesity & metabolism
Citation
Wang, Ning; Guo, Haonan; Song, Lin; Wang, Jingyue; Hu, Shuyuan; Wang, Mingxi; Zhang, Duowen; Jing, Yingyu; Zhang, Yifan; Wang, Mengjun; Wang, Ting; Sun, Bo. (2026). Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70571